Trial Profile
A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel Group, Multi-center Trial Assessing the Efficacy and Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) in Treatment of Adult Outpatients With Opioid Use Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 May 2023
Price :
$35
*
At a glance
- Drugs Buprenorphine (Primary) ; Buprenorphine/naloxone
- Indications Opioid-related disorders
- Focus Registrational; Therapeutic Use
- Sponsors Braeburn Pharmaceuticals
- 24 May 2023 According to a Camurus media release, company announces that the US Food and Drug Administration has approved Brixadi (buprenorphine) extended release injection for SC use, a weekly and monthly medication for the treatment of moderate to severe opioid use disorder, in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a daily buprenorphine product, the FDA approval of Brixadi was based this trial.
- 06 Apr 2019 Results of a post hoc analysis published in the Camurus Media Release
- 06 Apr 2019 Results presented in a Braeburn Pharmaceuticals media release.